IDO1 and neoplasm: Significantly, the released NLG919 was able to reversethe immunosuppressive TMME by inhibiting IDO and tumor infiltrationof Tregs, eventually inducing both primary and distant tumor regressionthrough PDT-sensitized immunotherapy.